Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands

Details for Australian Patent Application No. 2004209447 (hide)

Owner Pfizer Products Inc.

Inventors GRIFFITH, David, Andrew

Agent Shelston IP

Pub. Number AU-A-2004209447

PCT Pub. Number WO2004/069837

Priority 60/445,728 06.02.03 US

Filing date 26 January 2004

Wipo publication date 19 August 2004

International Classifications

C07D 487/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

A61K 031/53 - having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine

A61P 025/30 Drugs for disorders of the nervous system

C07D 251/00 Heterocyclic compounds containing 1,3,5-triazine rings

C07D 231/00 Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings

Event Publications

4 August 2005 PCT application entered the National Phase

  PCT publication WO2004/069837 Priority application(s): WO2004/069837

7 February 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004209452-Preparation of substituted quinazolines

2004209439-Method and composition for creation of conversion surface